Andina Capital Management LLC Acquires New Holdings in Zoetis Inc. (NYSE:ZTS)

Andina Capital Management LLC bought a new position in Zoetis Inc. (NYSE:ZTS) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,447 shares of the company’s stock, valued at approximately $286,000.

A number of other large investors have also added to or reduced their stakes in ZTS. Blue Bell Private Wealth Management LLC increased its position in shares of Zoetis by 222.5% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after purchasing an additional 89 shares during the last quarter. Independence Bank of Kentucky raised its holdings in Zoetis by 371.4% in the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock worth $33,000 after purchasing an additional 130 shares during the period. Ramirez Asset Management Inc. purchased a new position in Zoetis during the third quarter valued at $35,000. First Financial Corp IN increased its position in Zoetis by 57.2% in the fourth quarter. First Financial Corp IN now owns 217 shares of the company’s stock worth $43,000 after buying an additional 79 shares in the last quarter. Finally, FinTrust Capital Advisors LLC raised its stake in shares of Zoetis by 42.1% in the third quarter. FinTrust Capital Advisors LLC now owns 260 shares of the company’s stock worth $45,000 after buying an additional 77 shares during the period. Institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the sale, the executive vice president now owns 14,800 shares of the company’s stock, valued at $2,237,316. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 2,209 shares of company stock valued at $371,293 in the last 90 days. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on ZTS shares. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. The Goldman Sachs Group increased their price objective on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Piper Sandler restated an “overweight” rating and set a $195.00 price objective (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Barclays dropped their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 23rd. Finally, Stifel Nicolaus decreased their price target on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $216.13.

Zoetis Price Performance

ZTS stock traded down $0.68 during mid-day trading on Wednesday, hitting $158.56. The company had a trading volume of 1,884,129 shares, compared to its average volume of 3,130,864. The company has a market capitalization of $72.52 billion, a price-to-earnings ratio of 31.28, a P/E/G ratio of 2.44 and a beta of 0.85. The company has a 50-day moving average price of $170.66 and a 200 day moving average price of $179.12. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The business had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.19 billion. During the same period in the previous year, the company earned $1.15 EPS. Zoetis’s revenue for the quarter was up 8.5% compared to the same quarter last year. On average, research analysts anticipate that Zoetis Inc. will post 5.78 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be given a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 1.09%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is presently 34.12%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.